Neumora Therapeutics is trading at $1.79, up 8.5% in after-hours trading, rebounding from a sharp drop tied to failed Phase 3 trials and a major workforce reduction.
- The stock's recent decline followed the failure of its lead depression drug navacaprant and a subsequent 35% reduction in staff.
- No fresh company-specific news was reported on July 10, 2026; the move appears to be a recovery from June's heavy selloff and broader positive equity sentiment.